Editas licenses Cas9 to Vertex for CASGEVY; receives $50M upfront, extends runway to 2026

Editas Medicine, Inc.

Vertex gets non-exclusive Cas9 license for ex vivo BCL11A targeting sickle cell disease and beta thalassemia, including CASGEVY.
Editas receives $50M upfront cash, $50M contingent upfront, and annual license fees of $10M-$40M through 2034.
Editas must pay Broad Institute and Harvard a mid-double-digit percentage of amounts received from Vertex under the license.
Cash runway extended into 2026, combining existing cash with upfront and near-term fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.